

## TECHNICAL BRIEF

# Interim IPAC Recommendations and Use of PPE for Care of Individuals with Suspect or Confirmed Measles

Published: March 2024

## Key Messages

- All health care workers (HCWs) should have documented immunity to measles.<sup>1-19</sup> This consists of two doses of measles-containing vaccine or history of laboratory-confirmed infection or serological evidence of immunity, regardless of year of birth.<sup>20</sup> Only HCWs with presumptive immunity to measles should provide care to patients with suspect/confirmed measles due to increased risk of transmission of measles to susceptible individuals.<sup>21-24</sup>
- Recent scientific literature describes measles transmission and associated outbreaks in hospitals in both susceptible HCWs and in HCWs with presumptive immunity.<sup>4,5,14-17,25-27</sup>
- **All HCWs should wear a fit-tested, seal-checked N95 respirator when entering the room and/or caring for a patient with suspect/confirmed measles**, given reports of transmission of measles to HCWs with presumptive immunity.<sup>6,23,24,28</sup> Patients should also be placed in an airborne infection isolation room (AIIR) whenever possible.<sup>6,23,24,28-30</sup>
- Additional personal protective equipment (PPE) such as gloves, gown and eye protection may be added as required based on a point of care risk assessment (PCRA). For example, Additional Precautions for acute respiratory infection (ARI) (previously known as Droplet and Contact Precautions) are to be used for patients presenting with respiratory symptoms and/or undifferentiated viral symptoms.<sup>29,30</sup>

## Background

Measles cases and outbreaks have increased significantly globally over the past several years, becoming endemic again in countries where it had previously been eliminated (e.g., United Kingdom, Albania, Czech Republic and Greece). From 2022 to 2023, the World Health Organization (WHO) reported a 79% increase in global cases and outbreaks in 40 of 53 countries in the European region and ten EU/EEA countries.<sup>31-33</sup> Several factors have been implicated, including decline of measles vaccinations provided during the SARS-CoV-2 pandemic, as well as continued increase in vaccine hesitancy. In Canada, most measles cases are imported and outbreaks have been sporadic with limited secondary transmission.<sup>20</sup>

Recent scientific literature describes measles transmission and associated outbreaks in hospitals in both susceptible HCWs and in HCWs with presumed immunity.<sup>4-6,14-17,25-27</sup>

HCWs are at increased risk for occupationally acquired measles infection, in part due to increased exposure to patients who are ill with measles seeking health care.<sup>6,13,21</sup> Their risk is higher than the general population. Patients who are ill enough to be hospitalized are also generally at the peak of their communicability with high viremia and viral shedding.<sup>18,26</sup>

Between 2001 and 2014, six per cent of measles cases in the United States that were not imported cases, resulted from transmission in healthcare facilities.<sup>34</sup>

Given the transmissibility and potential for HCW exposure, there is consensus that only HCWs with presumptive evidence of immunity against measles should provide direct patient care to patients with suspect or confirmed measles. All HCWs should have documented immunity to measles.<sup>1-6,8,9,11-19,34-36</sup> Presumptive evidence of immunity for HCWs includes at least two doses of measles-containing vaccine received on or after their first birthday or laboratory evidence of immunity, regardless of year of birth.

In addition to the use of Routine Practices (RP), Additional Precautions are recommended for the care of patients with suspect/confirmed measles. Clinical presentations may vary and may evolve over time, thus a PCRA should always be performed before each patient encounter.

- Additional PPE such as gloves, gowns and eye protection may be added as required based on a PCRA. Precautions for respiratory particle protection (e.g. eye protection, facial protection, gown and gloves) are recommended for patients presenting with respiratory symptoms and/or undifferentiated viral symptoms.<sup>29,30</sup>
- Patient movement should be curtailed unless absolutely necessary. Where possible patient investigations/procedures should be conducted in the patient room with the patient wearing a medical mask, if tolerated. Should patient transport be required, use transport routes that minimize contacts and clear all hallways and elevators along the route. The patient should wear a medical mask, if tolerated, and HCWs assisting with transport should be wearing a fit-tested, seal-checked N95 respirator.<sup>29</sup>
- Although there is consensus for most recommended infection prevention and control (IPAC) practices for the management of suspect/confirmed measles, there is conflicting guidance amongst jurisdictions on the use of PPE as a control measure to reduce acquisition of nosocomial measles for HCWs with presumptive evidence of immunity:
  - Public Health Agency of Canada: “Immune HCWs do not require additional precautions (i.e., respirators) to enter the AIR of an individual with suspected or confirmed measles.”<sup>22</sup>
  - Centers for Disease Control and Prevention (CDC): “HCP should use respiratory protection (i.e., a respirator) that is at least as protective as a fit-tested, NIOSH-certified disposable N95 filtering facepiece respirator, regardless of presumptive evidence of immunity, upon entry to the room or care area of a patient with known or suspected measles.”<sup>23</sup>
  - National Health Service (NHS) England: “Staff should wear ‘respiratory protective equipment (RPE)’ defined as ‘a filtering face piece (FFP)’... when a patient is admitted with a known/suspected infectious agent/disease spread wholly or partly by the airborne route.”<sup>24</sup>

In order to ensure that IPAC recommendations regarding PPE are evidence-based where possible, and to address recent reports of measles acquired by HCWs with presumptive immunity, a literature search was conducted to inform any change in current IPAC recommendations.

## Methods

To identify relevant evidence on this topic, PHO Library Services designed and executed searches of scientific and grey literature. The search was limited to articles published in English from 2013 to present. The scientific databases were searched on March 5, 2024. The grey literature searches were run on March 7, 2024.

The following databases were searched to identify evidence published in scientific journals: MEDLINE (Ovid), and CINAHL (EBSCO).

To identify grey literature on this topic, several approaches were used. Targeted searches were run of websites of relevant public organizations, both national and international, such as the Public Health Agency of Canada (PHAC), Centers for Disease Control and Prevention (CDC), and the UK Health Services Authority (UKHSA). Searches were also run using the general search engines Google and Google Scholar.

The database search strategy was designed to retrieve records containing:

- At least one search term (in major topic heading, title keyword, or natural language descriptor fields) related to the concept of Measles; and
- At least one search term (in major topic heading, title keyword, or natural language descriptor fields) related to the concept of N95 Respirators;

The MEDLINE search strategy was adapted to create web search queries to find grey literature. These queries accommodated the limitations on the search engine functionality (e.g., 32 word limit per query), but the conceptual logic of the database search strategy was preserved. Since it is not practical or useful to review all the results retrieved by a search engine query, a limit of 50 results per query (ranked by relevancy) was manually enforced.

The MEDLINE search strategy (exactly as run) is available in Appendix A. The MEDLINE search strategy was peer-reviewed by members of the PHO Library Services team. Full search strategies are available upon request.

## Transmission of Measles to Health Care Workers

Reports of transmission of measles to HCWs are summarized below encompassing various measles outbreaks in hospitals throughout Europe, South Korea and the United States that have resulted in measles cases in not only susceptible HCWs but in those with a history of documented immunity.

Choi S, et al. in September 2023 described a measles outbreak in a hospital in South Korea in 2018 where two HCWs with presumptive evidence of measles immunity were infected by a patient with typical measles.<sup>17</sup> One worker had a history of two measles-containing vaccines and the other was presumed immune by age (born 1967).

Pampaka D, et al. in 2023 described a multi-regional outbreak in Spain involving 148 laboratory-confirmed cases of which six were epidemiologically linked.<sup>16</sup> The main route of transmission was nosocomial with at least six healthcare facilities and 41 HCWs affected.

Song K, et al. described in 2022 a measles outbreak in 2019 among previously vaccinated HCWs and patients.<sup>15</sup> Patients had laboratory-confirmed measles with throat swabs tested by quantitative polymerase chain reactions (PCR). Immunization records were obtained and among 26 measles case-

patients (22 HCWs, four inpatients) aged 18-28 years, 25 had previously received measles-mumps-rubella (MMR) vaccine and (12/26) 46% had received two doses.

Berry et al. described in 2019 a case in a hospital in England in 2017 where a late diagnosis in a case resulted in seven further confirmed cases, five of whom had received two doses of MMR vaccine.<sup>15</sup> This report highlighted the importance of not relying on vaccination status to rule out the diagnosis of measles.

Gohil S, et al. described an outbreak in Orange County California occurring in 2014.<sup>6</sup> Among 22 confirmed measles cases, five secondary cases occurred in HCWs, four having had direct contact with measles patients and none wore N95 respirators. Four HCWs had prior evidence of immunity and continued working after developing symptoms, resulting in 1014 exposures, but no transmissions. Overall, 13 of 15 secondary cases had face-to-face contact with measles patients, eight with prior evidence of immunity. Conclusions were that HCWs with unmasked, direct contact with measles patients are at risk for developing disease despite evidence of prior immunity, resulting in potentially large numbers of exposures and necessitating time-intensive investigations. The authors concluded that vaccination may lower infectivity. Regardless of immunity status, HCWs should wear N-95 respirators (or equivalent) when evaluating suspected measles patients.

Hahné S, et al. described a measles outbreak among HCWs in the Netherlands in 2014 published in 2016.<sup>5</sup> Eight HCWs became infected with measles and six of the eight had received two doses of measles vaccine.

López-Perea N, et al. described in the post-elimination phase of measles in Spain, an increasing proportion of measles appearing in individuals with two doses of vaccine.<sup>26</sup> The severity of illness and clinical presentation were milder among the vaccinated. One third of measles in fully vaccinated people was contracted in healthcare settings, mainly in doctors and nurses.

Bianchi FP, et al. conducted a systematic review and meta-analysis in 2022 to estimate the prevalence of susceptible HCWs in EU/EEA countries and in the UK and to explore the characteristics (sex and age differences).<sup>14</sup> Of nineteen studies included, the prevalence of measles-susceptible HCWs was 13.3% (95 %CI: 10.0-17.0%). In a comparison of age (born after vs. before 1980) the RR was 2.78 (95 %CI = 2.20-3.50) indicating those born later were at higher risk. The most recent studies proposed mandatory vaccination of HCWs.

In addition to discussion of measles transmission to HCWs with documented immunity, some authors addressed the lack of respiratory protection, and the role that may have played in transmission of measles to presumed immune HCWs and recommended routine use of a N95 fit-tested, seal-checked respirator.

## Hierarchy of Hazard Controls

Hierarchy of Hazard Controls IPAC practices can reduce the risk of infection transmission to patients, HCWs, as well as other staff and visitors, in all settings where health care is delivered. A Hierarchy of Controls (HOC) is used in health care settings (and other workplaces) to reduce the risk of transmission of infectious diseases.<sup>29,37,38</sup>

The hierarchy of hazard controls describes five levels of control, in decreasing order of effectiveness. The greatest reduction in hazard exposures often combines multiple levels. The highest level of control is Elimination, followed by Substitution, Engineering Controls, Administrative Controls and Personal

Protective Equipment. Used in combination, these strengthen the layers of protection of the worker against the hazard.

In applying the hierarchy of controls to protection of HCWs against acquisition of measles, elimination of the disease would be the most effective. Although there have been great strides toward elimination of measles within many countries, including Canada in 1998 achieving the status of having eliminated measles by the World Health Organization, there has been a resurgence of measles particularly in Europe and Africa.

The most common engineering control used in measles control is the placement of patients in an Airborne Infection Isolation Rooms (AIIR) where the air is under negative pressure and door is closed.

Key administrative controls include vaccination against measles. Other administrative controls include employee health policies and procedures regarding immunization and surveillance and IPAC programs with education of employees in the use of a PCRA and transmission-based precautions and training in the correct selection, use and disposal of PPE.

Finally, personal protective equipment is the last barrier between the hazard and the worker. As measles is transmitted through the airborne route, via small respiratory particles, a fit-tested, seal-checked N95 respirator is the recommended PPE for care of suspect/confirmed cases under Airborne Precautions.<sup>6,23,29,30</sup>

## Recommendations

- Consistent with the role of administrative controls in the hierarchy of controls, all acute care facilities should, beginning with their highest risk settings (including Emergency Departments), make immediate efforts to ensure that documented immunity to measles is in place for all HCWs and initiate investigation or vaccination for those with incomplete records.
- All HCWs regardless of presumptive immunity to measles should follow all IPAC recommendations for care of patients in Airborne Precautions, including wearing a fit-tested, seal-checked N95 respirator as an additional layer of protection and patient placement in an airborne infection isolation room (AIIR) whenever possible.
- Additional Precautions may also include PPE such as gloves, gown and eye protection based on a PCRA. For example, Additional Precautions for ARIs for respiratory particle protection (e.g. eye protection, facial protection, gown and gloves) are to be used for patients presenting with respiratory symptoms and/or undifferentiated viral symptoms.

## Summary

Despite significant global efforts to eliminate measles, there continues to be a resurgence of cases and outbreaks, including sporadic cases and outbreaks with limited secondary transmission in Canada. Health care facilities, including hospitals and primary care offices, where patients often present for diagnosis and/or treatment, increase the potential risk of HCW exposure to the disease. Although vaccination with two doses of measles-containing vaccine or positive serology suggests immunity, this presumptive immunity may not prevent HCWs from acquiring measles in the occupational setting. Following the hierarchy of controls and adding respiratory protection (fit-tested, seal-checked N95 respirator) to all workers regardless of immune status, while providing care to cases of suspect/confirmed measles offers an additional layer of protection.

## References

1. Tajima K, Nishimura H, Hongo S, Hazawa M, Saotome-Nakamura AI, Tomiyama K, et al. Estimation of secondary measles transmission from a healthcare worker in a hospital setting. *Int J Infect Dis*. 2014;24:11-3. Available from: <https://doi.org/10.1016/j.ijid.2014.03.1377>
2. Fiebelkorn AP, Seward JF, Orenstein WA. A global perspective of vaccination of healthcare personnel against measles: systematic review. *Vaccine*. 2014;32(38):4823-39. Available from: <https://doi.org/10.1016/j.vaccine.2013.11.005>
3. Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and Rubella Global Strategic Plan 2012-2020 midterm review. *Vaccine*. 2018;36 Suppl 1:A1-a34. Available from: <https://doi.org/10.1016/j.vaccine.2017.09.026>
4. de Vries W, Plötz FB, Dorigo-Zetsma JW. Measles infection despite 2-dose vaccination in health care workers. *Pediatr Infect Dis J*. 2014;33(9):992. Available from: <https://doi.org/10.1097/inf.0000000000000390>
5. Hahné SJ, Nic Lochlainn LM, van Burgel ND, Kerkhof J, Sane J, Yap KB, et al. Measles outbreak among previously immunized healthcare workers, the Netherlands, 2014. *J Infect Dis*. 2016;214(12):1980-6. Available from: <https://doi.org/10.1093/infdis/jiw480>
6. Gohil SK, Okubo S, Klish S, Dickey L, Huang SS, Zahn M. Healthcare workers and post-elimination era measles: lessons on acquisition and exposure prevention. *Clin Infect Dis*. 2016;62(2):166-72. Available from: <https://doi.org/10.1093/cid/civ802>
7. George F, Valente J, Augusto GF, Silva AJ, Pereira N, Fernandes T, et al. Measles outbreak after 12 years without endemic transmission, Portugal, February to May 2017. *Euro Surveill*. 2017;22(23). Available from: <https://doi.org/10.2807/1560-7917.Es.2017.22.23.30548>
8. Hiller U, Mankertz A, Köneke N, Wicker S. Hospital outbreak of measles - evaluation and costs of 10 occupational cases among healthcare worker in Germany, February to March 2017. *Vaccine*. 2019;37(14):1905-9. Available from: <https://doi.org/10.1016/j.vaccine.2019.02.068>
9. Coppeta L, Morucci L, Pietroiusti A, Magrini A. Cost-effectiveness of workplace vaccination against measles. *Hum Vaccin Immunother*. 2019;15(12):2847-50. Available from: <https://doi.org/10.1080/21645515.2019.1616505>
10. Park JW, Yu SN, Park E, Lee Y, Park SM, Jeon MH. Modified measles in an anti-measles immunoglobulin G-negative healthcare worker who had received two doses of measles-containing vaccine. *Infect Chemother*. 2019;51(3):305-9. Available from: <https://doi.org/10.3947/ic.2019.51.3.305>
11. Rana S, Saavedra-Campos M, Perkins S, Mohammed-Klein R, Wright A, Cordery R, et al. A descriptive analysis of an outbreak of measles and a multilevel mixed-effects analysis of factors associated with case isolation in healthcare settings, London (February-June 2016). *Public Health*. 2020;183:55-62. Available from: <https://doi.org/10.1016/j.puhe.2020.02.015>
12. Orsi A, Butera F, Piazza MF, Schenone S, Canepa P, Caligiuri P, et al. Analysis of a 3-months measles outbreak in western Liguria, Italy: are hospital safe and healthcare workers reliable? *J Infect Public Health*. 2020;13(4):619-24. Available from: <https://doi.org/10.1016/j.jiph.2019.08.016>

13. Camilloni B, Stracci F, Lio MC, Mencacci A, Cenci E, Bozza S. Measles immunity in healthcare workers of an Italian hospital. *J Infect Public Health*. 2020;13(8):1123-5. Available from: <https://doi.org/10.1016/j.jiph.2020.04.001>
14. Bianchi FP, Stefanizzi P, Trerotoli P, Tafuri S. Sex and age as determinants of the seroprevalence of anti-measles IgG among European healthcare workers: a systematic review and meta-analysis. *Vaccine*. 2022;40(23):3127-41. Available from: <https://doi.org/10.1016/j.vaccine.2022.04.016>
15. Song K, Lee JM, Lee EJ, Lee BR, Choi JY, Yun J, et al. Control of a nosocomial measles outbreak among previously vaccinated adults in a population with high vaccine coverage: Korea, 2019. *Eur J Clin Microbiol Infect Dis*. 2022;41(3):455-66. Available from: <https://doi.org/10.1007/s10096-021-04390-4>
16. Pampaka D, López-Perea N, Fernández-García A, Huertas-Zarco I, Castellanos-Martínez M, Villatoro-Bongiorno K, et al. An interregional measles outbreak in Spain with nosocomial transmission, November 2017 to July 2018. *Euro Surveill*. 2023;28(17). Available from: <https://doi.org/10.2807/1560-7917.Es.2023.28.17.2200634>
17. Choi S, Chung JW, Chang YJ, Lim EJ, Moon SH, Do HH, et al. A lesson from a measles outbreak among healthcare workers in a single hospital in South Korea: the importance of knowing the prevalence of susceptibility. *Vaccines (Basel)*. 2023;11(9). Available from: <https://doi.org/10.3390/vaccines11091505>
18. Limavady A, Tu IT, Bedford H. Guarding the gatekeepers: a comprehensive approach to control nosocomial measles. *Infection*. 2024 Feb 14 [Epub ahead of print]. Available from: <https://doi.org/10.1007/s15010-024-02186-0>
19. Vink JP, Snell LB, Bernard K, Mitchell H, Heathcock RT, Cordery R, Newsholme W. Mapping a nosocomial outbreak of measles, coinciding with a period of sustained transmission in South London in 2018. *J Hosp Infect*. 2020;105(4):747-51. Available from: <https://doi.org/10.1016/j.jhin.2020.06.004>
20. Public Health Agency of Canada; National Advisory Committee on Immunization; Committee to Advise on Tropical Medicine and Travel. Canadian immunization guide [Internet]. Evergreen ed. Ottawa, ON: Government of Canada; 2015 [modified 2023 Sept 8; cited 2024 Mar 11]. Part 4. Immunizing agents: measles vaccines. Available from: <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-12-measles-vaccine.html#p4c11t1>
21. Ontario Hospital Association; Ontario Medical Association. Measles surveillance protocol for Ontario hospitals. Toronto, ON: Ontario Hospital Association; 2019.
22. Public Health Agency of Canada, Measles and Rubella Elimination Working Group. Guidelines for the prevention and control of measles outbreaks in Canada. *Can Commun Dis Rep*. 2013;39(Ac-3):1-52. Available from: <https://doi.org/10.14745/ccdr.v39i00a03>
23. Centers for Disease Control and Prevention (CDC). Interim infection prevention and control recommendations for measles in healthcare settings [Internet]. Atlanta, GA: CDC; 2019 [modified 2019 Jul 23; cited 2024 Mar 11]. Available from: <https://www.cdc.gov/infectioncontrol/pdf/guidelines/Measles-Interim-IC-Recs-H.pdf>
24. NHS England. National infection prevention and control manual (NIPCM) for England [Internet]. London: Crown Copyright; 2024 [cited 2024 Mar 11]. Chapter 2: Transmission based precautions (TBPs). Available from: <https://www.england.nhs.uk/national-infection-prevention-and-control-manual-nipcm-for-england/>

25. Berry L, Palmer T, Wells F, Williams E, Sibal B, Timms J. Nosocomial outbreak of measles amongst a highly vaccinated population in an English hospital setting. *Infect Prev Pract.* 2019;1(2):100018. Available from: <https://doi.org/10.1016/j.infpip.2019.100018>
26. López-Perea N, Fernández-García A, Echevarría JE, de Ory F, Pérez-Olmeda M, Masa-Calles J. Measles in vaccinated people: epidemiology and challenges in surveillance and diagnosis in the post-elimination phase. Spain, 2014-2020. *Viruses.* 2021;13(10). Available from: <https://doi.org/10.3390/v13101982>
27. Zmerli O, Chamieh A, Maasri E, Azar E, Afif C. A challenging modified measles outbreak in vaccinated healthcare providers. *Infect Prev Pract.* 2021;3(1):100105. Available from: <https://doi.org/10.1016/j.infpip.2020.100105>
28. Alves Graber EM, Andrade FJ, Jr., Bost W, Gibbs MA. An update and review of measles for emergency physicians. *J Emerg Med.* 2020;58(4):610-5. Available from: <https://doi.org/10.1016/j.jemermed.2020.02.007>
29. Ontario Agency for Health Protection and Promotion (Public Health Ontario), Provincial Infectious Diseases Advisory Committee. Routine practices and additional precautions in all health care settings. 3<sup>rd</sup> ed. Toronto, ON: Queen's Printer for Ontario; 2012. Available from: <https://www.publichealthontario.ca/-/media/documents/b/2012/bp-rpap-healthcare-settings.pdf?la=en>
30. Public Health Agency of Canada. Routine practices and additional precautions for preventing the transmission of infection in healthcare settings. Ottawa, ON: Her Majesty the Queen in Right of Canada; 2016. Available from: <https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/diseases-conditions/routine-practices-precautions-healthcare-associated-infections/routine-practices-precautions-healthcare-associated-infections-2016-FINAL-eng.pdf>
31. Public Health Agency of Canada. Statement from the Chief Public Health Officer of Canada on global increase in measles and risk to Canada [Internet]. Ottawa, ON: Government of Canada; 2024 [cited 2024 Mar 11]. Available from: <https://www.canada.ca/en/public-health/news/2024/02/statement-from-the-chief-public-health-officer-of-canada-on-global-increase-in-measles-and-risk-to-canada.html>
32. World Health Organization (WHO). A 30-fold rise of measles cases in 2023 in the WHO European Region warrants urgent action. WHO [Internet], 2023 Dec 11 [cited 2024 Mar 11]; News. Available from: <https://www.who.int/europe/news/item/14-12-2023-a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-action>
33. European Centre for Disease Prevention and Control (ECDC). Measles on the rise in the EU/EEA: considerations for public health response-16 February 2024. Stockholm: ECDC; 2024. Available from: <https://www.ecdc.europa.eu/sites/default/files/documents/measles-eu-threat-assessment-brief-february-2024.pdf>
34. Fiebelkorn AP, Redd SB, Kuhar DT. Measles in Healthcare facilities in the United States during the postelimination era, 2001-2014. *Clin Infect Dis.* 2015;61(4):615-8. Available from: <https://doi.org/10.1093/cid/civ387>
35. Caplin B, Ashby D, McCafferty K, Hull R, Asgari E, Ford ML, et al. Risk of COVID-19 disease, dialysis unit attributes, and infection control strategy among London in-center hemodialysis patients. *Clin J Am Soc Nephrol.* 2021;16(8):1237-46. Available from: <https://doi.org/10.2215/cjn.03180321>



36. Park S, Mistrick R, Rim D. Performance of upper-room ultraviolet germicidal irradiation (UVGI) system in learning environments: effects of ventilation rate, UV fluence rate, and UV radiating volume. *Sustain Cities Soc.* 2022;85:104048. Available from: <https://doi.org/https://doi.org/10.1016/j.scs.2022.104048>
37. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Interim infection prevention and control measures based on respiratory virus transmission risks in health care settings [Internet]. 1<sup>st</sup> revision. Toronto, ON: King's Printer for Ontario; 2023 [modified 2023 Nov 30, cited 2024 Mar 11]. Available from: <https://www.publichealthontario.ca/-/media/Documents/I/2023/ipac-measures-transmission-risks-technical-brief.pdf>
38. Ontario Agency for Health Protection and Promotion (Public Health Ontario). IPAC recommendations for use of personal protective equipment for care of individuals with suspect or confirmed COVID-19 [Internet]. 3<sup>rd</sup> ed. Toronto, ON: King's Printer for Ontario; 2023 [cited 2024 Mar 11]. Available from: <https://www.publichealthontario.ca/-/media/documents/ncov/updated-ipac-measures-covid-19.pdf>

## Appendix A

**Table 1: Ovid MEDLINE(R) ALL <1946 to March 06, 2024>**

#	Searches
1	Measles/ or Measles Virus/ or (measles or (edmonston adj3 virus*) or rubeola).mp.
2	N95 Respirators/ or (N95 or "N-95" or N95s or "N-95s" or KN95 or "KN-95" or KN95s or "KN-95s").mp.
3	1 and 2
4	Measles/ or Measles Virus/ or (measles or (edmonston adj3 virus*) or rubeola).kf,kw,ti.
5	Masks/ or Respiratory Protective Devices/ or Personal Protective Equipment/ or ((facemask* or mask* or ((face or faces or facial or eyes or mouth or mouths or nose or noses) adj3 (protect* or PPE or cover* or mask* or respirator*)) or "respiratory protect*" or respirator* or "personal protective equipment" or ((protective or protection) adj3 (device* or equipment)) or PPE).kf,kw,ti. not medline.st.)
6	4 and 5
7	3 or 6
8	limit 7 to yr="2013 -Current"
9	limit 8 to English

## Citation

Ontario Agency for Health Protection and Promotion (Public Health Ontario). Technical brief: interim IPAC recommendations and use of PPE for care of individuals with suspect or confirmed measles. Toronto, ON: King's Printer for Ontario; 2024.

ISBN: 978-1-4868-7936-6

## Disclaimer

This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario's government, public health organizations and health care providers. PHO's work is guided by the current best available evidence at the time of publication. The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use. This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.

## Public Health Ontario

Public Health Ontario is an agency of the Government of Ontario dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit [publichealthontario.ca](https://publichealthontario.ca).

©King's Printer for Ontario, 2024

Ontario 